Outcome of infection with omicron SARS‐CoV ‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

Ola Blennow , Jon Salmanton-García , Piotr Nowak , Federico Itri , Jaap van Doesum , Alberto López-García , Francesca Farina , Ozren Jaksic , László Imre Pinczés , Yavuz Bilgin , Iker Falces-Romero , Moraima Jiménez , Irati Ormazabal-Vélez , Barbora Weinbergerová , Rémy Duléry , Zlate Stojanoski , Tobias Lahmer , Noemí Fernández , José‐ángel Hernández-Rivas , Verena Petzer , Nick de Jonge , Andreas Glenthøj , Cristina de Ramón , Monika Biernat , Nicola Fracchiolla , Avinash Aujayeb , Jens van Praet , Martin Schönlein , Gustavo‐adolfo Méndez , Chiara Cattaneo , Anna Guidetti , Mariarita Sciumè , Emanuele Ammatuna , Raul Cordoba , Nicole García-Poutón , Stefanie Gräfe , Alba Cabirta , Dominik Wolf , Anna Nordlander , Ramón García-Sanz , Mario Delia , Caroline Berg Venemyr , Clara Brones , Roberta Di Blasi , Elizabeth de Kort , Stef Meers , Sylvain Lamure (1, 2) , Laura Serrano , Maria Merelli , Nicola Coppola , Rui Bergantim , Caroline Besson , Milena Kohn , Jessica Petiti , Carolina Garcia-Vidal , Michelina Dargenio , François Danion , Marina Machado , Rebeca Bailén-Almorox , Martin Hoenigl , Giulia Dragonetti , Louis Yi Ann Chai , Chi Shan Kho , Matteo Bonanni , Raphaël Liévin , Francesco Marchesi , Oliver Cornely , Livio Pagano

1 CHU Montpellier
2 IGMM - Institut de Génétique Moléculaire de Montpellier

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused high mortality in patients with hematological malignancies (HM). 1 The newly emerged omicron variants of SARS-CoV-2 harbor multiple novel spike protein mutations that raise concerns about vaccine efficiency and antiviral efficacy of the available therapeutic monoclonal antibodies. 2 The first published clinical data in immunocompetent patients have found that infection with omicron variants is associated with reduced vaccine efficiency compared to the delta variants, but decreased hospital admission and mortality. 3,4 Preliminary, prepublished, data from a large case-control study have shown that the vaccine effect against omicron in immunocompromised patients, including HM patients, is even more reduced, but data regarding clinical outcomes are lacking. 5 The aim of this study was to describe risk factors, antiviral treatment and outcomes of SARS-CoV-2 omicron variant infection in 593 HM patients included in the EPICOVIDEHA registry. EPICOVIDEHA is an international open web-based registry for patients with HM infected with SARS-CoV-2. 1,6 Both hospitalized and nonhospitalized patients are eligible for inclusion. The questionnaire includes data on the HM, SARS-CoV-2 vaccination status, risk factors for severe COVID-19 infection, SARS-CoV-2 virus variant, antiviral treatment, and outcomes including mortality (eFigure 1 and eTable 4).

Domaines: Immunologie; Cancer; Hématologie

Ola Blennow, Jon Salmanton-García, Piotr Nowak, Federico Itri, Jaap van Doesum, et al.. Outcome of infection with omicron SARS‐CoV ‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report. American Journal of Hematology, 2022, 97 (8), ⟨10.1002/ajh.26626⟩. ⟨hal-03791162⟩